.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A08A_AntiobesityPreparationsExclDietProducts.A08AA62_BupropionAndNaltrexone.BupropionAndNaltrexone .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A08A_AntiobesityPreparationsExclDietProducts.A08AA62_BupropionAndNaltrexone.BupropionAndNaltrexone| name: | BupropionAndNaltrexone |
| ATC code: | A08AA62 | route: | oral |
| n-compartments | 1 |
The fixed-dose combination of bupropion and naltrexone is used for weight management as an adjunct to diet and exercise in adults with obesity or overweight with at least one weight-related comorbidity. Bupropion is a norepinephrine-dopamine reuptake inhibitor and naltrexone is an opioid antagonist. The combination is currently approved and marketed under brand names such as Contrave.
Estimated typical pharmacokinetic parameters for an adult population based on published PK profiles of individual components, as no population PK models for the combination have been published.